A Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 in Combination With BMS-986207 (Anti-TIGIT Antibody) and Nivolumab in Subjects With Advanced Solid Tumors.

Trial ID #	NCT04570839
Phase	I/II
Drug Class	Immunotherapy: Checkpoint Inhibitors/PVRIG
Drug Name	COM701
Drugs in Trial	BMS-986207, COM701, Nivolumab
Eligible Participant	Platinum resistant ovarian cancer
Patients Enrolled	20; median 4 prior therapies (1-10)
Therapy Setting	Recurrence
Study Design	Open-Label, Non-randomized
Endpoints	ORR, DCR, evaluated per RECIST
Efficacy	ORR: 20% (4PR - 3 HGSOC, 1 OCCC) DCR: 45% (4PR, 5SD)
Clinically Significant Adverse Events	Serious AE: Grade 3-4 AE: overall (35%)
Conclusion	The combination of COM701 + BMS-986207 + nivolumab is well tolerated and has encouraging durable anti-tumor activity with immune activation in patients with platinum resistant HGSOC and OCCC
Reference	Gaillard S et al. Durable responses with triple blockade of the DNAM-1 axis with COM701 + BMS-986207 + nivolumab in patients with platinum resistant ovarian cancer. J Immunother Cancer (2023) 11: abstract 669 https://jitc.bmj.com/content/11/Suppl_1/A758 Gaillard S et al. Poster https://www.clearityfoundation.org/wp-content/uploads/2024/01/COM701-poster-SITC-2023.pdf